A longitudinal case report examines discordant clinical improvement despite absent CFTR chloride biomarker response after triple-modulator therapy, plus AI-assisted chest CT monitoring.
Key Takeaways
- She has pancreatic insufficiency, progressive lung disease, and recurrent pulmonary exacerbations
- After ETI commencement (at 40.5 years; July 2021) SCC remained unchanged at ∼100 mmol/L
- BMI increased from 22.0 to 26.8 kg/m2